Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025GlobeNewsWire • 10/13/25
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO MagazineGlobeNewsWire • 10/01/25
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 AwardGlobeNewsWire • 09/23/25
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care DecisionsGlobeNewsWire • 09/09/25
Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside PotentialSeeking Alpha • 09/02/25
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 08/25/25
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/04/25
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 07/29/25
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/25
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business JournalGlobeNewsWire • 07/25/25
FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma TestGlobeNewsWire • 07/23/25
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong CultureGlobeNewsWire • 07/17/25
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025GlobeNewsWire • 07/14/25
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic DiseasesGlobeNewsWire • 06/16/25
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International ConventionGlobeNewsWire • 06/11/25
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®GlobeNewsWire • 06/04/25
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival OutcomesGlobeNewsWire • 05/29/25
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/21/25
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class ResultGlobeNewsWire • 05/09/25